Navigation Links
Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
Date:7/24/2012

clinical development and could fail at any time due to numerous unpredictable and significant risks related to safety, efficacy and other important findings that can negatively impact clinical development; (iv) the U.S. Food and Drug Administration and other health authorities could impose significant risk mitigation requirements that hamper the commercial potential of NKTR-181, even if this drug candidate receives regulatory approval; (v) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates such as NKTR-181 is therefore very uncertain and unpredictable and could unexpectedly fail at any time; (vi) patents may not issue from our patent applications for NKTR-181, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) the outcome of any existing or future intellectual property or other litigation related to our proprietary drug candidates.  Other important risks and uncertainties are detailed in our reports and other filings with the Securities and Exchange Commission ("SEC"), including without limitation, those risks and uncertainties set forth in our Form 10-Q for the quarter ended March 31, 2012, filed with the SEC on May 4, 2012. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
(Date:7/24/2014)... shows that incisionless transcatheter aortic valve replacement (TAVR) ... percent and has no impact on post-operative vascular ... which requires an incision in the groin. The ... of Circulation: Cardiovascular Interventions . , TAVR ... a traditional open-heart surgical approach. It is a ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
(Date:7/24/2014)... Angeles, CA (PRWEB) July 24, 2014 On ... loved ones will descend upon the Embassy Suites LAX North ... Conference hosted by DiabetesSisters and the first time it has ... first time for the organization to open the entire event ... As the only conference of its kind worldwide for women ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Human semen is ... microbes might have a role to play in both HIV ... that bacteria in semen -- the "microbiome" -- play a ... by infected men. They say the findings point to possible ... study couldn,t prove that the bacteria was causing changes in ...
Breaking Medicine News(10 mins):Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Bacteria in Semen May Affect HIV Transmission, Levels: Study 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: